The present invention concerns miRNAs for in vitro diagnosis of resistance of tumors to BRAF/MEK pathway inhibiting drugs by stimulating or inhibiting the expression of down-regulated or up-regulated miRNAs, respectively. Hence the interested tumors are characterized by BRAF mutation like: melanoma, colorectal cancer, papillary thyroid carcinoma, non small cell lung cancer, brain tumors, non-Hodgkin lymphoma. According to an embodiment of the present invention, the method can comprise measuring the expression of the following combinations of miRNAs listed from the most preferred: miR-199b-5p and miR-4488; miR-199b-5p and miR-4443; miR-4488 and miR-4443; miR-199b-5p, miR-4443 and miR-4488; miR-199b-5p and miR-204-5p.
MirRNAs for treatment and in vitro diagnosis of drug resistant tumors
Fattore L;Fattore L;
2019-01-01
Abstract
The present invention concerns miRNAs for in vitro diagnosis of resistance of tumors to BRAF/MEK pathway inhibiting drugs by stimulating or inhibiting the expression of down-regulated or up-regulated miRNAs, respectively. Hence the interested tumors are characterized by BRAF mutation like: melanoma, colorectal cancer, papillary thyroid carcinoma, non small cell lung cancer, brain tumors, non-Hodgkin lymphoma. According to an embodiment of the present invention, the method can comprise measuring the expression of the following combinations of miRNAs listed from the most preferred: miR-199b-5p and miR-4488; miR-199b-5p and miR-4443; miR-4488 and miR-4443; miR-199b-5p, miR-4443 and miR-4488; miR-199b-5p and miR-204-5p.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
